Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium cromoglicate is a small molecule mast cell stabilizer developed and manufactured by Basic Pharma Manufacturing for the treatment of allergic conditions. It is formulated as a nasal spray for allergic rhinitis and as eye drops for allergic conjunctivitis. The drug acts by preventing the degranulation of sensitized mast cells, thereby inhibiting the release of histamine, leukotrienes, and other inflammatory mediators. This stabilization is thought to be mediated through the inhibition of calcium influx and potentially via agonism of the G protein-coupled receptor 35 (GPR35). As a prophylactic agent, it is most effective when used before exposure to allergens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium cromoglicate.